Kimmtrak (Tebentafusp)

Tebentafusp is a bispecific fusion protein that combines a soluble T‑cell receptor targeting the gp100 peptide on melanoma cells with an anti‑CD3 fragment that binds T‑cells. This dual binding activates T‑cells, leading to cytokine release and targeted killing of the cancer cells.

The dosing regimen for Kimmtrak is determined by the prescribing oncologist based on the patient’s weight, HLA status, and clinical condition. The medication is administered as an intravenous infusion under medical supervision.

Safety data for Tebentafusp in pregnancy or lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To order Kimmtrak, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kimmtrak is a targeted immunotherapy that uniquely redirects patient T‑cells to gp100‑expressing tumor cells, offering a mechanism distinct from conventional chemotherapy or checkpoint inhibitors. Clinical studies have shown improved overall survival compared with historical controls, though direct head‑to‑head trials are limited.

Kimmtrak must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to infusion, the product should be inspected for particulates and used within the time frame specified by the manufacturer.

Kimmtrak is given as an intravenous infusion in a clinical setting. The infusion rate is controlled by the healthcare provider, and patients are monitored for infusion‑related reactions and vital signs throughout the administration.

The most serious risks include severe cytokine release syndrome, cardiac events such as arrhythmias or myocarditis, neurotoxicity, pulmonary edema, and anaphylaxis. Prompt recognition and management of these events are critical during and after infusion.

Kimmtrak is contraindicated in patients with known hypersensitivity to Tebentafusp or any of its excipients, and it should be used with caution in individuals with uncontrolled infections, severe cardiac disease, or those receiving live vaccines. A thorough clinical assessment is required before initiation.